tachycardia
TACHYCARDIA

Tachycardia or tachyarrhythmia is used to describe the presence of cardiac rhythm abnormality in states when cardiac rate is increased to >100 bpm.

Divided into supraventricular and ventricular tachycardia.

Signs and symptoms related to rapid heart rate are altered sensorium, angina, shortness of breath, myocardial infarction, hypotension and other signs of shock (eg cold clammy skin, low urine output), heart failure or pulmonary congestion.

Control Strategy for Atrial Fibrillation

  • Lenient heart rate (HR) control, compared to strict HR control, may be beneficial in patients with persistent atrial fibrillation who have stable ventricular function (left ventricular [LV] ejection fraction >0.40) and/or no symptoms related to atrial fibrillation
    • LV function should be monitored in these patients
    • Lenient HR control is defined as achieving resting HR <110 beats per minute (bpm); strict HR control is <80 bpm at rest and HR <110 bpm during a 6-minute walk
  • One trial revealed that in patients with atrial fibrillation and systolic heart failure, routine strategy of rhythm control is not beneficial compared to rate control strategy
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 06 Sep 2017

In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor significantly reduces bleeding vs triple therapy with warfarin, a P2Y12 inhibitor and aspirin, with comparable rates of thromboembolic events, results of the RE-DUAL PCI trial have shown.

19 Jun 2019
Slideshow: Highlights from the Asian Pacific Society of Cardiology 2019 Congress
Yesterday
A study has recently derived and validated a new index for preoperative cardiovascular evaluation, which can significantly contribute to the efficient triage and management of patients scheduled for noncardiac surgery. The new Cardiovascular Risk Index (CVRI) demonstrates a robust discriminatory power that can effectively stratify patients into low-, intermediate- and high-risk groups.
04 Jun 2019
The addition of alirocumab to intensive statin therapy appears to cut the risk of death following acute coronary syndrome, especially if treatment is sustained for at least 3 years, if baseline low-density lipoprotein cholesterol (LDL-C) is ≥100 mg/dL or if achieved LDL-C is low, according to data from the ODYSSEY OUTCOMES.